CLSA sets target of Rs 830 on Star Health
Star Health's core strengths - innovative product suite, largest individual agent base and in-house-claim management - will continue to support Star in gaining or maintaining market share in a fast-growing industry, said CLSA.

The health insurer's strong position in a fast-growing industry should support its revenue growth and market share gains, said CLSA.
Star Health's core strengths - innovative product suite, largest individual agent base and in-house-claim management - will continue to support Star in gaining or maintaining market share in a fast-growing industry, said CLSA.
The stock is down 22% from the IPO price of ₹900. The stock had listed at a near 6% discount to its IPO price of ₹848.80 in December last year.

"We expect the industry to expand three times plus in the next five years with gross premiums growing from $4 billion to $12 billion and net population (excluding below poverty and government employees) covered by retail policies to increase from 6% today to 11%," said CLSA.
"Star's innovative products, wide distribution, hospital network, in-house claim management and focus on the profitable retail segment should support 29% CAGR in premiums over next two years and return on equity expansion to 20% in FY24," said CLSA.
Download ET Markets APP